The future of Orphazyme A/S is up in the air after regulators in the EU followed the stance of their US peers in rejecting arimoclomol, the Danish biotech's treatment for the ultra-rare disorder Niemann-Pick disease type C (NPC).
Uncertain Future For Orphazyme After EMA Snub
Agency Set To Reject Arimoclomol For Niemann-Picks Type C
The EMA's medicines evaluation committee has told Orphazyme it will not approve the rare disease drug arimoclomol when it meets at the end of March, prompting the Danish firm to assess its strategic options.
More from Rare Diseases
More from Scrip
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.